Last reviewed · How we verify
NCT03652376
Impact of Benralizumab Treatment on Circulating Dendritic Cells in Patients With Eosinophilic Asthma
Phase 4 trial testing Benralizumab in Severe Eosinophilic Asthma in 20 participants. Status unknown.
1 May 2019
Quick facts
| Lead sponsor | University of Rostock |
|---|---|
| Phase | Phase 4 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 20 |
| Start date | 1 September 2018 |
| Primary completion | 1 May 2019 |
| Estimated completion | 31 December 2019 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- Benralizumab (BENRALIZUMAB) — full drug profile →
Conditions studied
- Severe Eosinophilic Asthma — all drugs for Severe Eosinophilic Asthma →
Sponsor
University of Rostock
Who can join
Adults 18 to 75, any sex, with Severe Eosinophilic Asthma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study investigates the effect of removing eosinophils from peripheral blood (using treatment with Benralizumab, which is approved for the treatment of severe eosoniphilic asthma) on circulating dendritic cells in patients with severe eosinophilic asthma.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03652376
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Benralizumab
Trials testing the same drug.
- NCT07444567 — Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit Fr · Phase 3 · not yet recruiting
- NCT06512883 — A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases · Phase 3 · recruiting
- NCT06465485 — STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma · Phase 3 · active not recruiting
- NCT06385236 — Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping · Phase 4 · recruiting
- NCT05966584 — A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer · Phase 2 · terminated
Other recruiting trials for Severe Eosinophilic Asthma
Currently open trials in the same condition.
- NCT07214753 — A Real-life Observational Study in Severe Eosinophilic Asthma Adult Participant Treated With Benralizumab in Italy · recruiting
- NCT06465485 — STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma · Phase 3 · active not recruiting
- NCT06069310 — Mepolizumab Effectiveness in Patients With Chronic Rhinosinusitis, Nasal Polyps and Comorbid Severe Eosinophilic Asthma · active not recruiting
Other University of Rostock trials
Trials by the same sponsor.
- NCT06489470 — Strokectomy in Malignant Cerebral Media Infarction · NA · recruiting
- NCT06175429 — Prognostic Value of Exhaled Isoprene Levels for Morbidity and Functional Outcome in Cardiosurgical Patients · unknown
- NCT04972617 — Characterization of the Efficacy of Furosemide Depending on Albumin Function · completed
- NCT06318208 — Pulmonary Function in Non-hospitalized Adults and Children After Mild COVID-19 · completed
- NCT05885620 — SAMi Intervention Study to Evaluate Smartwatch Interventions in Persons With MCI and Dementia · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03652376 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Rostock
- Last refreshed: 29 August 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03652376.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing